Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04969861
Title BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Nektar Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | AUT

Additional content available in CKB BOOST